Hagiwara, Yasuhiro http://orcid.org/0000-0003-3792-5368
Sawaki, Masataka
Uemura, Yukari
Kawahara, Takuya
Shimozuma, Kojiro
Ohashi, Yasuo
Takahashi, Masato
Saito, Tsuyoshi
Baba, Shinichi
Kobayashi, Kokoro
Mukai, Hirofumi
Taira, Naruto
Funding for this research was provided by:
Comprehensive Support Project for Oncology Research of the Public Health Research Foundation
Article History
Received: 18 March 2021
Accepted: 4 May 2021
First Online: 2 June 2021
Declarations
:
: YU reports honoraria from Chugai Pharma and Teijin Pharma; consulting and advisory role for Pfizer, Ono Pharmaceutical, Zeria Pharmaceutical, and Daiichi Sankyo; speakers' bureaus for Pfizer; and travel support from Pfizer and Chugai Pharma. YO reports compensated leadership for Statcom; stock ownership of Statcom; honoraria from Chugai Pharma, Daiichi Sankyo, Sanofi, Eisai, and Shionogi; and grants from Medical Member System. MT reports honoraria from AstraZeneca, Eli Lilly, Eisai, and Pfizer; and grants paid to the institution from Eisai, Kyowa Kirin, and Taiho Pharmaceutical. HM reports honoraria from Pfizer, Daiichi Sankyo, Taiho Pharmaceutical, and Takeda; and grants paid to the institution from Daiichi Sankyo. All remaining authors have declared no conflicts of interest.
: The RESPECT trial protocol, including the cognitive functioning sub-study, was approved by the institutional review boards of all participating institutions.
: All patients provided written informed consent.